Biogen CEO sees no burning need for more acquisitions
By Deena Beasley SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 ...
Read moreDetailsTag: Sage Therapeutics
Biogen proposes to buy remaining stake in Sage in $442 million deal
(Reuters) - Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 ...
Read moreDetails
